Siltuximab, the monoclonal antibody with a high binding affinity for IL-6, showed therapeutic activity in patients with platinum-resistant ovarian cancer in Phase II clinical trial (Nowak and Klink, 2020) (Figure 1). The gene discussed is IL6; the disease is ovarian carcinoma.